Correction for Shtykova et al., “Solution Structure, Self-Assembly, and Membrane Interactions of the Matrix Protein from Newcastle Disease Virus at Neutral and Acidic pH”

Штыкова, Э. В.; Petoukhov, Maxim V.; Dadinova, L. A.; Федорова, Н. В.; Tashkin, V. Yu.; Тимофеева, Т. А.; Ksenofontov, Alexander L.; Loshkarev, Nikita A.; Baratova, L. A.; Jeffries, Cy M.; Svergun, D. I.; Batishchev, Oleg V.

doi:10.1128/jvi.00580-21

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the nuclear capsid can maintain higher stability under acidic conditions, many studies have suggested that weak acidic conditions trigger a viral decapsidation effect, causing remodeling of the capsid protein. Some of the oncolytic viruses that have been shown to decapsidize under weak acidic conditions are Newcastle disease virus [ 26 ], adenovirus [ 27 ], herpes simplex virus [ 28 ], and coxsackievirus [ 29 ]. For example, weak acidic conditions cause the nucleic acids of adenoviruses to coalesce, and stronger acidic conditions are observed at pH 4 when the capsid is stiff and more prone to rupture, while structural rearrangement of the capsid protein can be observed at pH 6 [ 27 ].…”

Section: Chemical Factorsmentioning

confidence: 99%

Study of Oncolytic Virus Preservation and Formulation

et al. 2023

View full text Add to dashboard Cite

In recent years, oncolytic viruses (OVs) have emerged as an effective means of treating cancer. OVs have multiple oncotherapeutic functions including specifically infecting and lysing tumor cells, initiating immune cell death, attacking and destroying tumor angiogenesis and triggering a broad bystander effect. Oncolytic viruses have been used in clinical trials and clinical treatment as drugs for cancer therapy, and as a result, oncolytic viruses are required to have long-term storage stability for clinical use. In the clinical application of oncolytic viruses, formulation design plays a decisive role in the stability of the virus. Therefore, this paper reviews the degradation factors and their degradation mechanisms (pH, thermal stress, freeze–thaw damage, surface adsorption, oxidation, etc.) faced by oncolytic viruses during storage, and it discusses how to rationally add excipients for the degradation mechanisms to achieve the purpose of maintaining the long-term stability of oncolytic viral activity. Finally, the formulation strategies for the long-term formulation stability of oncolytic viruses are discussed in terms of buffers, permeation agents, cryoprotectants, surfactants, free radical scavengers, and bulking agent based on virus degradation mechanisms.

show abstract